Shares have plunged by a third in the past year. Investors are worried about expiring patents for Keytruda, the cancer ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Recent advancements in Merck's (MRK) product portfolio, including the FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan and several approvals of their flagship drug KEYTRUDA, are ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Stamford: SpringWorks Therapeutics, Inc., a healthcare company of Merck, has received marketing authorization from the ...

Merck KGaA, the German science and technology group, lowered its full-year sales growth forecast as it grapples with a weaker ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck’s acquisition strategy clearly reflects its commitment to constructing a portfolio extending beyond oncology. For instance, the recent $680 million acquisition of Harpoon Therapeutics ...

Merck, in some respects, is leaning into risk-taking. And the dinner represented the all-hands-on-deck effort to develop the next generation of cancer therapies that will puncture the status quo ...

Merck isn't the only pharmaceutical company making an antiviral pill for COVID-19. But Merck's pill is farther along in the process and could become the first antiviral drug approved to be taken ...